(Q44162437)

30 November 2017

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects (English)

1 reference

30 November 2017

1 reference

Joel Morganroth

1

1 reference

30 November 2017

Peter C Rüegg

2

1 reference

30 November 2017

Cornelia Dunger-Baldauf

3

1 reference

30 November 2017

Silke Appel-Dingemanse

4

1 reference

30 November 2017

Harald Bliesath

5

1 reference

30 November 2017

Martin Lefkowitz

6

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

The American Journal of Gastroenterology

30 November 2017

1 reference

30 November 2017

97

1 reference

30 November 2017

9

1 reference

30 November 2017

2321-2327

1 reference

Long QT syndrome during high-dose cisapride

30 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

Long QT syndromes and torsade de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

Do human atrial 5-HT4 receptors mediate arrhythmias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

Review article: irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05986.X

10.1111/J.1572-0241.2002.05986.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference